Thirty-day outcomes post-discharge
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
| Early discharge (n=107) | Late discharge (n=358) | p Value | Early discharge (n=89) | Late discharge (n=178) | p Value | |
| Death | 2 (1.9)* | 6 (1.7) | 0.583 | 2 (2.2)* | 3 (1.7) | 0.540 |
| New PPM | 0 (0.0) | 2 (0.6) | 0.592 | 0 (0.0) | 2 (1.1) | 0.444 |
| Any bleeding | 1 (0.9) | 0 (0.0) | 0.230 | 1 (1.1) | 0 (0.0) | 0.333 |
| Re-hospitalisation | 1 (0.9) | 3 (0.8) | 0.650 | 1 (1.1) | 2 (1.1) | 1.000 |
| Composite safety endpoint† | 3 (2.8) | 8 (2.2) | 0.483 | 3 (3.4) | 5 (2.8) | 0.533 |
| Acute kidney injury‡ | ||||||
| Stage 1 | 5 (4.6) | – | – | 4 (4.5) | – | – |
| Stage 2 | 1 (0.9) | – | – | 1 (1.1) | – | – |
| Stage 3 | 0 (0.0) | – | – | 0 (0.0) | – | – |
Values are n (%). Categorical variables were compared using the McNemar's exact test.
*Patient #1 (CoreValve 29 mm, no conduction disturbances at discharge) died at day 11 due to haemorrhagic stroke. Patient #2 (CoreValve 29 mm and PPM implanted at day 1) died at day 9 due to myocardial infarction.
†Defined as the composite of death, bleeding, PPM implantation, and re-hospitalisation for any cause.
‡Available in patients discharged within 3 days after TAVI. Outcome defined according to blood work prescribed at days 5–7 after discharge.
PPM, permanent pacemaker; TAVI, transcatheter aortic valve implantation.